MUSCLE-INVASIVE BLADDER CANCER

This phase II trial tests whether adding the immunotherapy drug durvalumab after surgery, chemotherapy, and radiation can help prevent bladder cancer from coming back in people with muscle-invasive bladder cancer. About 82 participants will receive either durvalumab or a placebo …

This phase 3 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a targeted therapy (enfortumab vedotin) works better than current standard care for people with muscle-invasive bladder cancer who cannot take or refuse cisplatin chemotherapy. A…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help people with muscle-invasive bladder cancer live longer without their cancer returning or spreading. About 520 participants who are eligible for non-surgical treatment will …

This study tests whether adding immunotherapy drugs (nivolumab, with or without BMS-986205) to standard chemotherapy before and after bladder cancer surgery helps more people achieve a complete response and live longer without the cancer returning. About 855 adults with muscle-in…

This study tests whether starting immunotherapy earlier—based on a blood test that finds tumor DNA—can control bladder cancer that may have spread after the bladder is removed. About 154 adults whose cancer has returned or is at high risk of spreading will receive the treatment. …

This study tests whether the immunotherapy drug atezolizumab can delay or prevent bladder cancer from coming back after surgery. It includes 761 high-risk patients whose blood tests showed cancer DNA after bladder removal. Participants receive either atezolizumab or a placebo to …

This phase 2 trial is testing a combination of three drugs—sacituzumab govitecan, zimberelimab, and domvanalimab—given before and after surgery for muscle-invasive bladder cancer. The study includes 70 patients who cannot take standard cisplatin chemotherapy. The main goal is to …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer. About 1,063 participants will receive either the drug combo or standard care. The goal is to see i…

This early-phase study tests a combination of two drugs—romidepsin and durvalumab—given directly into the bladder for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy. The goal is to see if the combination is safe and can shrink or eliminate tum…

This study tests whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) before bladder cancer surgery is safe and does not delay the operation. The goal is to shrink the tumor, making surgery more effective. It involves 52 adults with muscle-invasive bladder canc…

This phase 2 trial tests whether giving a live BCG vaccine directly into the bladder, followed by immunotherapy (atezolizumab) and standard chemotherapy (cisplatin/gemcitabine), can completely clear muscle-invasive bladder cancer before patients undergo bladder removal surgery. T…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) is safe and works better for people with advanced bladder cancer. About 54 participants will receive the combination treatment. The goal is to see if the combo…

This study tests whether the immunotherapy drug nivolumab, given after standard chemo-radiation, can help prevent bladder cancer from coming back. About 200 adults with localized muscle-invasive bladder cancer who cannot have bladder removal surgery are taking part. The main goal…

This study is for people with muscle-invasive bladder cancer that has gotten worse after earlier treatments. It tests several different drug combinations, chosen based on the specific genetic markers of each person's tumor. The main goal is to see if these combinations are safe a…

This Phase 2 trial tests whether adding visugromab to the immunotherapy nivolumab helps shrink muscle-invasive bladder cancer before surgery. The study includes 31 patients who cannot take or refuse standard cisplatin chemotherapy. The main goal is to see how many patients have n…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab can help control muscle-invasive bladder cancer in patients who cannot undergo bladder removal surgery. About 79 participants will receive atezolizumab after standard chemo-radiotherapy. The main goal is to…

This phase II trial tests a combination of an immunotherapy drug called sasanlimab and focused radiation given before bladder removal surgery in 33 patients with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if this approach is safe, fea…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) alone or with entinostat affects immune markers in people with muscle-invasive bladder cancer who cannot or choose not to have standard chemotherapy. Twenty participants receive the drugs before the…